As of August 2025, ARE's current EPS stands at -$0.13, according to the latest financial reports. For the year 2024, the company recorded an earnings per share (EPS) of $1.8, which marks an increase compared to its EPS of $0.54 in 2023. ARE reported an EPS of -$0.64 for the quarterly report ending on Jun 30, 2025.
For 2024, Alexandria Real Estate Equities's EPS was $1.8, an increase of 233.3% from $0.54 in 2023. For the fiscal quarter that ended on Jun 30, 2025, the per-share earnings was -$0.64, showing a 356% decrease from the same quarter last year. For the twelve months ending June 2025, the EPS is -$0.13. For the year 2023, the yearly earnings per share was $0.54, marking a decrease of 83% from 2022.
Alexandria Real Estate Equities has registered a decrease in EPS of 356% during the last 12 months (YoY, quarterly). Examining a broader timeline, the company maintained an average EPS growth rate of -22.3% per year for the last three years. Alexandria Real Estate Equities had an average annual EPS growth rate of -10.5% during the last 5 years. A 10-year view shows that ARE has seen an average EPS growth of 5.9% per year.
Stock name | Price to Earnings | EPS grwoth 1Y | EPS grwoth 3Y | EPS grwoth 5Y |
---|---|---|---|---|
ILMN Illumina Inc | 11.94 | -4.8% | N/A | N/A |
PFE Pfizer Inc | 13.01 | 273.7% | -28.7% | -13.2% |
BMY Bristol Myers Squibb Co | 18.45 | -213.7% | N/A | N/A |
AMGN Amgen Inc | 23.4 | -39.3% | -9.7% | -10.1% |
GILD Gilead Sciences Inc | 23.65 | -91.6% | -57.5% | -38.3% |
LLY ELI LILLY & Co | 40.76 | 102.1% | 24.1% | 5.7% |
ALNY Alnylam Pharmaceuticals Inc | N/A | 38.1% | N/A | N/A |
ARE Alexandria Real Estate Equities Inc | N/A | 233.3% | -22.3% | -10.5% |
All data is based on quarterly TTM periods, unless otherwise specified.